度普利尤单抗治疗特应性皮炎后出现斑秃。 - Suppr

Suppr

超能文献

Alopecia areata after dupilumab for atopic dermatitis.

作者信息

Mitchell Krystal, Levitt Jacob

机构信息

University of Oklahoma College of Medicine, Oklahoma City, Oklahoma.

The Mount Sinai Medical Center, Department of Dermatology, New York, New York.

出版信息

JAAD Case Rep. 2018 Jan 16;4(2):143-144. doi: 10.1016/j.jdcr.2017.11.020. eCollection 2018 Mar.

DOI:10.1016/j.jdcr.2017.11.020

PMID:29387767

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5790019/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b33a/5790019/934e73413ff1/gr1.jpg

相似文献

Alopecia areata after dupilumab for atopic dermatitis.

JAAD Case Rep. 2018 Jan 16;4(2):143-144. doi: 10.1016/j.jdcr.2017.11.020. eCollection 2018 Mar.

Remission of alopecia universalis in a patient with atopic dermatitis treated with dupilumab.

JAAD Case Rep. 2019 Jan 12;5(2):116-117. doi: 10.1016/j.jdcr.2018.11.007. eCollection 2019 Feb.

Full scalp hair regrowth in a 4-year-old girl with alopecia areata and atopic dermatitis treated with dupilumab.

JAAD Case Rep. 2020 Oct 15;6(12):1286-1287. doi: 10.1016/j.jdcr.2020.10.010. eCollection 2020 Dec.

[Dupilumab-Associated Healing of Alopecia Areata in an Atopic Dermatitis Patient].

Dtsch Med Wochenschr. 2019 May;144(9):602-605. doi: 10.1055/a-0836-3119. Epub 2019 Apr 26.

[Hair growth with dupilumab in alopecia areata universalis and atopic dermatitis].

Dermatologie (Heidelb). 2022 Jul;73(7):556-559. doi: 10.1007/s00105-021-04898-y. Epub 2021 Oct 5.

Long-Term Efficacy of Dupilumab in Alopecia Areata.

Am J Case Rep. 2022 Jun 21;23:e936488. doi: 10.12659/AJCR.936488.

Remission of Alopecia Universalis after 1 Year of Treatment with Dupilumab in a Patient with Severe Atopic Dermatitis.

Skin Appendage Disord. 2022 Jan;8(1):38-41. doi: 10.1159/000517832. Epub 2021 Jul 27.

Improvement of alopecia areata with Dupilumab in a patient with severe atopic dermatitis and review the literature.

Australas J Dermatol. 2020 May;61(2):e223-e225. doi: 10.1111/ajd.13208. Epub 2019 Nov 25.

Improvement of atopic dermatitis and alopecia universalis with dupilumab.

Dermatol Reports. 2021 Dec 28;14(2):9359. doi: 10.4081/dr.2022.9359. eCollection 2022 Jun 16.

Dupilumab for the treatment of alopecia areata in pediatric patients with atopic dermatitis: A scoping review.

Pediatr Dermatol. 2024 Nov-Dec;41(6):1123-1126. doi: 10.1111/pde.15691. Epub 2024 Jul 4.

引用本文的文献

Alopecia Areata Associated with Dupilumab: National Database Study.

Diagnostics (Basel). 2025 Jul 21;15(14):1828. doi: 10.3390/diagnostics15141828.

Case Report: Omalizumab-associated hair loss: a case of eyebrow alopecia areata, literature review and FAERS database analysis.

Front Med (Lausanne). 2025 Jun 27;12:1605826. doi: 10.3389/fmed.2025.1605826. eCollection 2025.

Dupilumab and Alopecia Areata: A Possible Combined or Disturbance Therapy? A Review of The Literature.

Dermatol Pract Concept. 2024 Oct 30;14(4):e2024270. doi: 10.5826/dpc.1404a270.

Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective.

Dermatol Reports. 2023 Sep 13;16(2):9839. doi: 10.4081/dr.2023.9839. eCollection 2024 Jun 14.

Case report: Sequential therapy with dupilumab and baricitinib for severe alopecia areata with atopic dermatitis in children.

Front Immunol. 2024 Jun 6;15:1395288. doi: 10.3389/fimmu.2024.1395288. eCollection 2024.

Long-term, observational, real-world study of dupilumab for the treatment of moderate-to-severe atopic dermatitis: a 52-week single-center retrospective analysis in China.

Arch Dermatol Res. 2024 May 31;316(6):304. doi: 10.1007/s00403-024-03029-6.

Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib.

Front Med (Lausanne). 2023 Oct 9;10:1253795. doi: 10.3389/fmed.2023.1253795. eCollection 2023.

Delayed Hyperpigmented Injection Site Reactions Due to Chronic Dupilumab Use.

Cureus. 2023 Apr 11;15(4):e37441. doi: 10.7759/cureus.37441. eCollection 2023 Apr.

Short communication: Comments on hair disorders associated with dupilumab based on VigiBase.

PLoS One. 2022 Jul 27;17(7):e0270906. doi: 10.1371/journal.pone.0270906. eCollection 2022.

Biologic Therapies for the Management of Cutaneous Findings in Genodermatoses: A Review.

Am J Clin Dermatol. 2022 Sep;23(5):673-688. doi: 10.1007/s40257-022-00700-4. Epub 2022 May 23.

本文引用的文献

IL-4Rα Inhibitor for Atopic Disease.

Cell. 2017 Jul 13;170(2):222. doi: 10.1016/j.cell.2017.06.046.

The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm.

Adv Ther. 2017 Jul;34(7):1594-1609. doi: 10.1007/s12325-017-0542-7. Epub 2017 Jun 23.

Dupilumab: First Global Approval.

Drugs. 2017 Jul;77(10):1115-1121. doi: 10.1007/s40265-017-0768-3.

Cellular and molecular immunologic mechanisms in patients with atopic dermatitis.

J Allergy Clin Immunol. 2016 Aug;138(2):336-49. doi: 10.1016/j.jaci.2016.06.010.

Three months of rifapentine and isoniazid for latent tuberculosis infection.

N Engl J Med. 2011 Dec 8;365(23):2155-66. doi: 10.1056/NEJMoa1104875.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Alopecia areata after dupilumab for atopic dermatitis.

作者信息

Mitchell Krystal, Levitt Jacob

机构信息

University of Oklahoma College of Medicine, Oklahoma City, Oklahoma.

The Mount Sinai Medical Center, Department of Dermatology, New York, New York.

出版信息

JAAD Case Rep. 2018 Jan 16;4(2):143-144. doi: 10.1016/j.jdcr.2017.11.020. eCollection 2018 Mar.

DOI:10.1016/j.jdcr.2017.11.020

PMID:29387767

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5790019/

Abstract

摘要

相似文献

Alopecia areata after dupilumab for atopic dermatitis.

JAAD Case Rep. 2018 Jan 16;4(2):143-144. doi: 10.1016/j.jdcr.2017.11.020. eCollection 2018 Mar.

Remission of alopecia universalis in a patient with atopic dermatitis treated with dupilumab.

JAAD Case Rep. 2019 Jan 12;5(2):116-117. doi: 10.1016/j.jdcr.2018.11.007. eCollection 2019 Feb.

Full scalp hair regrowth in a 4-year-old girl with alopecia areata and atopic dermatitis treated with dupilumab.

JAAD Case Rep. 2020 Oct 15;6(12):1286-1287. doi: 10.1016/j.jdcr.2020.10.010. eCollection 2020 Dec.

[Dupilumab-Associated Healing of Alopecia Areata in an Atopic Dermatitis Patient].

Dtsch Med Wochenschr. 2019 May;144(9):602-605. doi: 10.1055/a-0836-3119. Epub 2019 Apr 26.

[Hair growth with dupilumab in alopecia areata universalis and atopic dermatitis].

Dermatologie (Heidelb). 2022 Jul;73(7):556-559. doi: 10.1007/s00105-021-04898-y. Epub 2021 Oct 5.

Long-Term Efficacy of Dupilumab in Alopecia Areata.

Am J Case Rep. 2022 Jun 21;23:e936488. doi: 10.12659/AJCR.936488.

Remission of Alopecia Universalis after 1 Year of Treatment with Dupilumab in a Patient with Severe Atopic Dermatitis.

Skin Appendage Disord. 2022 Jan;8(1):38-41. doi: 10.1159/000517832. Epub 2021 Jul 27.

Improvement of alopecia areata with Dupilumab in a patient with severe atopic dermatitis and review the literature.

Australas J Dermatol. 2020 May;61(2):e223-e225. doi: 10.1111/ajd.13208. Epub 2019 Nov 25.

Improvement of atopic dermatitis and alopecia universalis with dupilumab.

Dermatol Reports. 2021 Dec 28;14(2):9359. doi: 10.4081/dr.2022.9359. eCollection 2022 Jun 16.

Dupilumab for the treatment of alopecia areata in pediatric patients with atopic dermatitis: A scoping review.

Pediatr Dermatol. 2024 Nov-Dec;41(6):1123-1126. doi: 10.1111/pde.15691. Epub 2024 Jul 4.

引用本文的文献

Alopecia Areata Associated with Dupilumab: National Database Study.

Diagnostics (Basel). 2025 Jul 21;15(14):1828. doi: 10.3390/diagnostics15141828.

Case Report: Omalizumab-associated hair loss: a case of eyebrow alopecia areata, literature review and FAERS database analysis.

Front Med (Lausanne). 2025 Jun 27;12:1605826. doi: 10.3389/fmed.2025.1605826. eCollection 2025.

Dupilumab and Alopecia Areata: A Possible Combined or Disturbance Therapy? A Review of The Literature.

Dermatol Pract Concept. 2024 Oct 30;14(4):e2024270. doi: 10.5826/dpc.1404a270.

Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective.

Dermatol Reports. 2023 Sep 13;16(2):9839. doi: 10.4081/dr.2023.9839. eCollection 2024 Jun 14.

Case report: Sequential therapy with dupilumab and baricitinib for severe alopecia areata with atopic dermatitis in children.

Front Immunol. 2024 Jun 6;15:1395288. doi: 10.3389/fimmu.2024.1395288. eCollection 2024.

Long-term, observational, real-world study of dupilumab for the treatment of moderate-to-severe atopic dermatitis: a 52-week single-center retrospective analysis in China.

Arch Dermatol Res. 2024 May 31;316(6):304. doi: 10.1007/s00403-024-03029-6.

Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib.

Front Med (Lausanne). 2023 Oct 9;10:1253795. doi: 10.3389/fmed.2023.1253795. eCollection 2023.

Delayed Hyperpigmented Injection Site Reactions Due to Chronic Dupilumab Use.

Cureus. 2023 Apr 11;15(4):e37441. doi: 10.7759/cureus.37441. eCollection 2023 Apr.

Short communication: Comments on hair disorders associated with dupilumab based on VigiBase.

PLoS One. 2022 Jul 27;17(7):e0270906. doi: 10.1371/journal.pone.0270906. eCollection 2022.

Biologic Therapies for the Management of Cutaneous Findings in Genodermatoses: A Review.

Am J Clin Dermatol. 2022 Sep;23(5):673-688. doi: 10.1007/s40257-022-00700-4. Epub 2022 May 23.

本文引用的文献

IL-4Rα Inhibitor for Atopic Disease.

Cell. 2017 Jul 13;170(2):222. doi: 10.1016/j.cell.2017.06.046.

The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm.

Adv Ther. 2017 Jul;34(7):1594-1609. doi: 10.1007/s12325-017-0542-7. Epub 2017 Jun 23.

Dupilumab: First Global Approval.

Drugs. 2017 Jul;77(10):1115-1121. doi: 10.1007/s40265-017-0768-3.

Cellular and molecular immunologic mechanisms in patients with atopic dermatitis.

J Allergy Clin Immunol. 2016 Aug;138(2):336-49. doi: 10.1016/j.jaci.2016.06.010.

Three months of rifapentine and isoniazid for latent tuberculosis infection.

N Engl J Med. 2011 Dec 8;365(23):2155-66. doi: 10.1056/NEJMoa1104875.